These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34301030)

  • 21. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil.
    Khattab WM; Zein El-Dein EE; El-Gizawy SA
    Drug Dev Ind Pharm; 2020 May; 46(5):795-805. PubMed ID: 32275456
    [No Abstract]   [Full Text] [Related]  

  • 23. Formulation and
    Ahmed MM; Fatima F; Anwer MK; Ibnouf EO; Kalam MA; Alshamsan A; Aldawsari MF; Alalaiwe A; Ansari MJ
    Saudi Pharm J; 2021 May; 29(5):467-477. PubMed ID: 34135673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Product development studies on surface-adsorbed nanoemulsion of olmesartan medoxomil as a capsular dosage form.
    Singh S; Pathak K; Bali V
    AAPS PharmSciTech; 2012 Dec; 13(4):1212-21. PubMed ID: 22965661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
    Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
    Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability.
    Lee BS; Kang MJ; Choi WS; Choi YB; Kim HS; Lee SK; Lee J; Choi YW
    Arch Pharm Res; 2009 Nov; 32(11):1629-35. PubMed ID: 20091278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation and evaluation of Piroxicam nanosponge for improved internal solubility and analgesic activity.
    Gaber DA; Radwan MA; Alzughaibi DA; Alail JA; Aljumah RS; Aloqla RM; Alkhalifah SA; Abdoun SA
    Drug Deliv; 2023 Dec; 30(1):2174208. PubMed ID: 36744372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
    Cushman WC; Bakris GL; White WB; Weber MA; Sica D; Roberts A; Lloyd E; Kupfer S
    J Hypertens; 2018 Apr; 36(4):947-956. PubMed ID: 29334491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.
    Ferdinand KC; Bakris GL; Cushman WC; Weber MA; Lloyd E; Wu J; White WB
    Am J Cardiol; 2018 Nov; 122(9):1496-1505. PubMed ID: 30217371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solubility determination and solution thermodynamics of olmesartan medoxomil in (PEG-400 + water) cosolvent mixtures.
    Al-Shdefat R
    Drug Dev Ind Pharm; 2020 Dec; 46(12):2098-2104. PubMed ID: 33151111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization and In Vitro Characterization of Telmisartan Loaded Sodium Alginate Beads and Its In Vivo Efficacy Investigation in Hypertensive Induced Animal Model.
    Uthumansha U; Prabahar K; Gajapathy DB; El-Sherbiny M; Elsherbiny N; Qushawy M
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis.
    Kumar L; Khuwaja S; Kumar A; Memon UA; Kumar M; Ashok A; Lohana M; Qudoos A; Kashif M; Khatri M; Kumar S; Sapna F; Dass A; Varrassi G
    Cureus; 2023 Jun; 15(6):e41198. PubMed ID: 37525792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability.
    Dora CP; Trotta F; Kushwah V; Devasari N; Singh C; Suresh S; Jain S
    Carbohydr Polym; 2016 Feb; 137():339-349. PubMed ID: 26686138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and formulation of polymeric nanosponge tablets with enhanced solubility for combination therapy.
    Moin A; Roohi NKF; Rizvi SMD; Ashraf SA; Siddiqui AJ; Patel M; Ahmed SM; Gowda DV; Adnan M
    RSC Adv; 2020 Sep; 10(57):34869-34884. PubMed ID: 35514416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
    Volpe M; Christian Rump L; Ammentorp B; Laeis P
    Clin Drug Investig; 2012 Oct; 32(10):649-64. PubMed ID: 22909147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olmesartan niosomes ameliorates the Indomethacin-induced gastric ulcer in rats: Insights on MAPK and Nrf2/HO-1 signaling pathway.
    Sallam AM; Darwish SF; El-Dakroury WA; Radwan E
    Pharm Res; 2021 Nov; 38(11):1821-1838. PubMed ID: 34853982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
    Alsofany JM; Hamza MY; Abdelbary AA
    AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
    Pandya NT; Jani P; Vanza J; Tandel H
    Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
    Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
    Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.